US 10258606
Endothelin single nucleotide polymorphisms and methods of predicting β-adrenergic receptor targeting agent efficacy
granted A61KA61K31/404A61K31/4045
Quick answer
US patent 10258606 (Endothelin single nucleotide polymorphisms and methods of predicting β-adrenergic receptor targeting agent efficacy) held by The Regents of the University of Colorado, a Body Corporate expires Mon Apr 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The Regents of the University of Colorado, a Body Corporate
- Grant date
- Tue Apr 16 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Apr 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 6
- CPC classes
- A61K, A61K31/404, A61K31/4045, A61P, A61P9/00